Evidence map›Paper›PMID 35372066›Full record

ArticleFrontiers in oncology2022

Impact of IDH1 c.315C>T SNP on Outcomes in Acute Myeloid Leukemia: A Propensity Score-Adjusted Cohort Study.

Elizabeth M Corley, Moaath K Mustafa Ali, Hanan Alharthy, Kathryn A F Kline, Danielle Sewell, Jennie Y Law, Seung Tae Lee, Sandrine Niyongere, Vu H Duong, Maria R Baer and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Impact ofBiology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Elizabeth M CorleySchool of Medicine, University of Maryland, Baltimore, Baltimore, MD, United States.
Moaath K Mustafa AliGreenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, Baltimore, MD, United States.
Hanan AlharthyDepartment of Medicine, School of Medicine, University of Maryland, Baltimore, Baltimore, MD, United States.
Kathryn A F KlineGreenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, Baltimore, MD, United States.
Danielle SewellTranslational Genomics Laboratory, Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, Baltimore, MD, United States.
Jennie Y LawGreenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, Baltimore, MD, United States.
Seung Tae LeeGreenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, Baltimore, MD, United States.
Sandrine NiyongereGreenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, Baltimore, MD, United States.
Vu H DuongGreenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, Baltimore, MD, United States.
Maria R BaerGreenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, Baltimore, MD, United States.
Ashkan EmadiGreenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, Baltimore, MD, United States.
University of Maryland, Baltimore · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute myeloid leukemia (AML) is the common type of acute leukemia in adults. Definitive prognostic significance of variants of unknown significance lacks for many commonly mutated genes, including the isocitrate dehydrogenase 1 (IDH1) synonymous single nucleotide polymorphism (SNP) variant c.315C>T. In this retrospective cohort study of 248 AML patients at the University of Maryland Greenebaum Comprehensive Cancer Center, we show that the IDH1 c.315C>T SNP, previously reported to be associated with poor prognosis by other studies with conflicting data, does not confer worse prognosis, with a median overall survival (OS) of 17.1 months compared to 15.1 months for patients without this SNP (P=0.57). The lack of negative effect on prognosis by IDH1 SNP c.315C>T is consistent with the absence of amino acid alteration (p.Gly105Gly).

Indexed as

AMLIDH1 c.315C>T SNPMyeloid mutationsprognosissurvival

Identifiers

PMID35372066
PMCPMC8972959
OpenAlexW4220945932

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.